Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
61.3.9653.9160
Address
Suite 1 Level 9 432 St Kilda Road Melbourne, Victoria (VIC) 3004
Description
Respiri Ltd. engages in research, development, and commercialization of medical devices and the production of mobile health applications for management of asthma and related chronic respiratory diseases. Its proprietary apps, software, and devices will help people monitor the symptoms of their conditions, increase their awareness of risk of attack, adhere to their medication plans, improve outcomes, and reduce healthcare expenditures. The firm operates through the Australia and Israel segments. The Australia segment includes research, development, and commercialization of medical devices, and the production of mobile health applications in Australia. The Israel segment refers to the research, development and, commercialization of medical devices, and the production of mobile health applications in Israel. The company was founded by Noam Gavriely in 1987 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.02 - 0.04
Trade Value (12mth)
AU$4,172.00
1 week
0%
1 month
20.83%
YTD
0%
1 year
-27.5%
All time high
6.57
EPS 3 yr Growth
-43.300%
EBITDA Margin
%
Operating Cashflow
-$4m
Free Cash Flow Return
-227.30%
ROIC
-292.30%
Interest Coverage
-418.30
Quick Ratio
0.80
Shares on Issue (Fully Dilluted)
906m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
22 July 24 |
Respiri raises $3 million through Placement
×
Respiri raises $3 million through Placement |
22 July 24 |
Proposed issue of securities - RSH
×
Proposed issue of securities - RSH |
22 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
02 July 24 |
Change of Company Auditor
×
Change of Company Auditor |
18 June 24 |
Cleansing Prospectus
×
Cleansing Prospectus |
18 June 24 |
Application for quotation of securities - RSH
×
Application for quotation of securities - RSH |
18 June 24 |
Application for quotation of securities - RSH
×
Application for quotation of securities - RSH |
13 June 24 |
Notification of cessation of securities - RSH
×
Notification of cessation of securities - RSH |
05 June 24 |
Respiri Raises $1 Million Through Additional Placement
×
Respiri Raises $1 Million Through Additional Placement |
05 June 24 |
Proposed issue of securities - RSH
×
Proposed issue of securities - RSH |
09 May 24 |
May 2024 Investor Presentation
×
May 2024 Investor Presentation |
03 May 24 |
Change of Director's Interest Notice - MM
×
Change of Director's Interest Notice - MM |
03 May 24 |
Change of Director's Interest Notice - NS
×
Change of Director's Interest Notice - NS |
02 May 24 |
Respiri Market Update Presentation
×
Respiri Market Update Presentation |
01 May 24 |
Notification regarding unquoted securities - RSH
×
Notification regarding unquoted securities - RSH |
30 April 24 |
Respiri Raises $1.6 million through Additional Placement
×
Respiri Raises $1.6 million through Additional Placement |
30 April 24 |
Proposed issue of securities - RSH
×
Proposed issue of securities - RSH |
30 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
29 April 24 |
RSH contracts first Hawaii independent physician association
×
RSH contracts first Hawaii independent physician association |
18 April 24 |
Results of Meeting
×
Results of Meeting |
19 March 24 |
Notice of General Meeting/Proxy Form
×
Notice of General Meeting/Proxy Form |
19 March 24 |
2024 GM - Letter to Shareholders & Proxy Form
×
2024 GM - Letter to Shareholders & Proxy Form |
08 March 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
29 February 24 |
Appendix 4D and Half Year Financial Report
×
Appendix 4D and Half Year Financial Report |
31 January 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.